Entrinsic Health Solutions in partnership with the Markey Cancer Center, today announced clinical data from a pilot study examining the anti-diarrheal efficacy of enterade®, an amino acid based solution, in neuroendocrine tumor (NET) patients. Aman Chauhan, MD, Hematology and Oncology Fellow at the University of Kentucky, presented the results during a poster session titled, “The Anti-diarrheal Efficacy of an Amino Acid Mixture in Neuroendocrine Tumor (NET) Patients” at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium held in San Francisco from January 18 – 20, 2018.
The purpose of the study was to evaluate if enterade® could help boost gastrointestinal (GI) function and reduce diarrhea frequency in 33 NET patients. A total of 33 subjects were treated and efficacy data was available on 17 of those subjects by the time of the presentation. Results concluded that 76% (13/17) of neuroendocrine tumor patients reported improvement in diarrhea with enterade® and 76.9% (10/13) reported more than 50% reduction in diarrhea frequency after one week of treatment. With no sugar to exacerbate GI dysfunction, enterade® can reduce diarrhea related to cancer treatment, leading to an improvement in patients’ overall quality of life and a healthier GI system.